Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

47 world leading UK researchers, including the Department's Georg Hollander and Andrew Pollard have been elected to the prestigious Fellowship of the Academy of Medical Sciences.

The Fellows have been elected for their contribution to medical research and healthcare, the generation of new knowledge in medical sciences and its translation into benefits to society.

Read more here

Similar stories

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

The Oxford-Harrington Rare Disease Centre initiates first disease priority area: Friedreich’s Ataxia

The Oxford-Harrington Rare Disease Centre is redoubling efforts to develop a therapeutics programme for Friedreich’s Ataxia.

Innovation award for Paediatrics researcher to develop new treatments for childhood cancer

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Celebrating Early Careers Researchers on International Women's Day

In these short interviews, Anna Kordala and Jane Millar talk about the research they do at the Department of Paediatrics.

Professor Matthew Snape named NIHR Senior Investigator

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.